Patent details

Title (priority date) Uses and methods relating to NDR kinaseexpression and/or activity (29.11.2006)
Reference: 047
Inventors: Cornils, Dirnhofer & Hemmings
Description: The inventors observed that lymphoma development due to abherant NDR1 and/or NDR2 expression is late onset. This suggest that early detection of abherant NDR1 and/or NDR2 expression may allow for treatmetn before disease ocurs.
Applications: Cancer therapy, screening for anti-cancer agents
Status: EP pending
Opportunity: Exclusive or non-exclusive licenses
Contact: Dr. Nicolas Favre, tel: +41 61 6978382, e-mail:
PCT File: WO2008/065391
About this site2019 © FMI Basel Switzerland